These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24247426)

  • 1. Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists.
    Clyne M
    Nat Rev Urol; 2013 Dec; 10(12):679. PubMed ID: 24247426
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
    Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
    Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.
    Carneiro A; Sasse AD; Wagner AA; Peixoto G; Kataguiri A; Neto AS; Bianco BA; Chang P; Pompeo AC; Tobias-Machado M
    World J Urol; 2015 Sep; 33(9):1281-9. PubMed ID: 25387877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
    Merseburger AS; Sedding D; Hüter K
    Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved.
    Bourke L; Chico TJ; Albertsen PC; Hamdy FC; Rosario DJ
    Heart; 2012 Mar; 98(5):345-8. PubMed ID: 22155645
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic side effects of androgen deprivation therapy in prostate cancer.
    Lafontaine ML; Kokorovic A
    Curr Opin Support Palliat Care; 2022 Dec; 16(4):216-222. PubMed ID: 36349380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies.
    Scailteux LM; Naudet F; Alimi Q; Vincendeau S; Oger E
    Medicine (Baltimore); 2016 Jun; 95(24):e3873. PubMed ID: 27310974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens and prostate cancer; pathogenesis and deprivation therapy.
    Grossmann M; Cheung AS; Zajac JD
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.
    Muniyan S; Xi L; Datta K; Das A; Teply BA; Batra SK; Kukreja RC
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188383. PubMed ID: 32535158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
    Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH
    J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
    Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
    BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer.
    Kohutek ZA; Weg ES; Pei X; Shi W; Zhang Z; Kollmeier MA; Zelefsky MJ
    Urology; 2016 Jan; 87():146-52. PubMed ID: 26476405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of FSH and LH in prostate cancer and cardiometabolic comorbidities.
    Crawford ED; Schally AV
    Can J Urol; 2020 Apr; 27(2):10167-10173. PubMed ID: 32333736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
    Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.